Latest news
2cureX announces launch of updated Specimen Collection Set
Read more
The power of precision.
For every cancer patient.
Today.
Press releases & news
-
2cureX announces launch of updated Specimen Collection Set
Read more -
2cureX Newsletter
Read more -
2cureX publishes interim report for the fourth quarter and full year of 2022
Read more -
Invitation to 2cureX webcast on Year-End Report and latest news on February 24, 2023
Read more
Latest report
Share Information
See our latest share informationCalendar & upcoming events
-
Commentary on Q2 2023 report – Infront Direkt Studios will host an interview with CEO Fernando Andreu regarding the results presented in the Q2 2023 report.
Read more -
2cureX Webcast – Get the latest news from the second quarter of 2023 and Q&A with the Management of 2cureX.
Sign up -
All things permitting, we look forward to seeing you all at ESMO GI again this summer. We will be there in Barcelona in person from 28 June – 1 July. More details to follow.
Go to event -
Commentary on Q1 2023 report – Infront Direkt Studios will host an interview with CEO Fernando Andreu regarding the results presented in the Q1 2023 report.
Read more
CEO Blog
In his latest blog, CEO Fernando Andreu talks about the real-life benefit of using IndiTreat®
Subscribe to our newsletter at the bottom of the page.
More
Information for Oncologists and Pathologists
Know more when it matters most:
With our IndiTreat® tests you can finally obtain personalised information, even on the classic compounds for the main chemotherapy backbone for your stage IV mCRC patients.
Information for Patients
You’ve been diagnosed with colorectal cancer, and it is in stage IV. There are rational treatment choices to be made. Which therapy is more likely to impact the tumor? Ask your doctor about IndiTreat®.
More
A paradigm shift in cancer treatment
2cureX is introducing a new way in which treatment decisions are made. In this article, Raphael Gruber, our Medical Director talks about this paradigm shift in cancer treatment decisions.
More